Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Cuts A New Path But Remains Rooted In Primary Care

This article was originally published in The Pink Sheet Daily

Executive Summary

Forest’s new CEO outlined “Project Rejuvenate,” a strategy to recharge the drug marketer, Dec. 2. The program involves headcount and cost reductions and the sale of $1 billion in debt to fund share repurchases and bolt-on acquisitions. But the plan doesn’t call for a change in strategic direction since Saunders intends to strengthen Forest’s commitment to primary care.

You may also be interested in...



Will Saunders Bring Transformation To Forest?

The specialty pharma long has been scrutinized for its decisions regarding the patent cliff and business development. Now, a new CEO will have the chance to keep the company on its current course or mirror the transformations he’s put in motion at other companies.

Forest’s Fetzima Will Test Enantiomer Exclusivity Policy Change

The antidepressant levomilnacipran, an enantiomer of Forest’s fibromyalgia drug Savella (milnacipran), could be the first product to take advantage of an FDA Amendments Act provision that allows enantiomers of previously approved drugs to qualify for five years of new chemical entity exclusivity.

Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'

Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.

Topics

Related Companies

UsernamePublicRestriction

Register

PS075207

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel